Benzinga

Benzinga

Benzinga

lunes, agosto 24

Madrigal Pharmaceuticals Inc

MDGLNASDAQ
Trade with Public
Trade with Public
$512.26
-4.48-0.87%
Últ. Act.: Aug 24, 1:38 PM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Madrigal Pharmaceuticals Financials

Madrigal Pharmaceuticals (MDGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over losses of $(2.61) per
Benzinga Newsdesk

PRO
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate

Benzinga Newsdesk

Earnings Scheduled For February 19, 2026

Benzinga Insights

Earnings Preview For Madrigal Pharmaceuticals

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved